ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

cobimetinib

Also written as “Cobimetinib”, “HM95573, cobimetinib” and “GDC-0973 IV Infusion”.

Its studies are mostly in Melanoma · Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms · Neoplasms · Ovarian Neoplasms, led by 2 companies.

Drug pageCobimetinib: every studyAll 94 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Sep 18, 201238 company-led studies, 6 open or runningNext primary completion: Nov 30, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche364 open or runningphase 3since Sep 18, 2012Apr 18, 2007Nov 30, 2026phase 2 · NCT04302025
Hanmi Pharmaceuticalits history only22 open or runningphase 2since Feb 27, 2026Aug 7, 2017Sep 2029phase 2 · NCT07449754

Also a collaborator on its studies: Halozyme Therapeutics and BioLineRx.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Hoffmann-La Roche only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 22 studies since Apr 18, 2007.

  1. Aug 18, 2016Phase 1 study in Colorectal NeoplasmsNCT02876224 · 51 enrolled · United States, Spain
  2. Jun 1, 2017Phase 1 study in MelanomaNCT03178851 · 155 enrolled · United States, Australia, Bosnia and Herzegovina and more
  3. Jun 5, 2017Phase 3 study in Carcinoma, Non-Small-Cell LungNCT03178552 · 1,000 enrolled · United States, Argentina, Australia and more
  4. Jun 9, 2017Phase 2 study in Pancreatic AdenocarcinomaNCT03193190 · 341 enrolled · United States, Germany, Japan and more
  5. Aug 17, 2017Phase 2 study in Solid TumorsNCT03264066 · 87 enrolled · United States, Belgium, Germany and more
  6. Sep 1, 2017Phase 3 study in Advanced BRAFV600 Wild-type MelanomaNCT03273153 · 446 enrolled · United States, Australia, Belgium and more
  7. Sep 11, 2017Phase 2 study in Esophageal NeoplasmsNCT03281369 · 219 enrolled · United States, Australia, Israel and more
  8. Oct 12, 2017Phase 2 study in Multiple MyelomaNCT03312530 · 49 enrolled · Czechia, Denmark, France and more
  9. Nov 7, 2017Phase 2 study in Carcinoma, Non-Small-Cell LungNCT03337698 · 314 enrolled · United States, Australia, France and more
  10. Aug 2, 2018Phase 2 study in MelanomaNCT03625141 · 80 enrolled · Brazil, France, Germany and more
  11. Sep 30, 2018Phase 1 study in Ovarian NeoplasmsNCT03695380 · 77 enrolled · United States, Italy, Spain
  12. Mar 6, 2020Phase 2 study in Carcinoma, Non-Small-Cell LungNCT04302025 · 99 enrolled · United States
  13. Apr 6, 2021Phase 1 study in MelanomaNCT04835805 · 65 enrolled · United States, Australia, Canada and more
  14. Jun 9, 2021Phase 2 study in Ovarian NeoplasmsNCT04931342 · 176 enrolled · United States, Australia, Canada and more

Ahead

  1. Nov 30, 2026Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT04302025
  2. Dec 31, 2026Primary completion: phase 1 study in MelanomaNCT04835805
  3. Jun 30, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT03178552
  4. Feb 28, 2028Primary completion: phase 2 study in Ovarian NeoplasmsNCT04931342

TargetBeta

“Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor; Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
pimasertibruleMerck KGaA, Darmstadt, Germanyphase 213
mirdametinibruleMerck KGaA, Darmstadt, Germanyphase 29
polfurmetinibPfizerphase 13

Studies

All 36 Hoffmann-La Roche leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04931342Ovarian Neoplasms · United States, Australia, Canada and more2Active, not recruitingFeb 28, 2028176
NCT04835805Melanoma · United States, Australia, Canada and more1Active, not recruitingDec 31, 202665
NCT04302025Carcinoma, Non-Small-Cell Lung · United States2Active, not recruitingNov 30, 202699
NCT03695380Ovarian Neoplasms · United States, Italy, Spain1CompletedJul 12, 202377
NCT03625141Melanoma · Brazil, France, Germany and more2CompletedJun 7, 202180
NCT03337698Carcinoma, Non-Small-Cell Lung · United States, Australia, France and more2TerminatedOct 14, 2025314
NCT03312530Multiple Myeloma · Czechia, Denmark, France and more2CompletedMay 18, 202149
NCT03281369Esophageal Neoplasms · United States, Australia, Israel and more2TerminatedOct 9, 2025219
NCT03273153Advanced BRAFV600 Wild-type Melanoma · United States, Australia, Belgium and more3TerminatedApr 15, 2019446
NCT03264066Solid Tumors · United States, Belgium, Germany and more2CompletedJun 25, 202087
NCT03193190Pancreatic Adenocarcinoma · United States, Germany, Japan and more2CompletedFeb 27, 2025341
NCT03178552Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3Active, not recruitingJun 30, 20271,000
NCT03178851Melanoma · United States, Australia, Bosnia and Herzegovina and more1CompletedMay 29, 2019155
NCT02876224Colorectal Neoplasms · United States, Spain1CompletedJun 25, 201951
NCT02788279Colorectal Neoplasms · United States, Australia, Belgium and more3CompletedMar 9, 2018363
NCT02670044Leukemia, Myeloid, Acute · United States, Canada, France and more1CompletedDec 10, 202088
NCT02639546Solid Tumors · United States, France, Germany and more2CompletedJul 21, 202156
NCT02457793Carcinoma, Non-Small-Cell Lung · United States1CompletedDec 5, 201624
NCT02322814Breast Neoplasms · United States, Australia, Belgium and more2TerminatedAug 10, 2018169
NCT02300025Healthy Volunteer · United States1CompletedJan 201528
NCT02291289Colorectal Neoplasms · Argentina, Belgium, Bosnia and Herzegovina and more2CompletedMay 31, 20191,044
NCT02136524Healthy Volunteer · United States1CompletedMay 201428
NCT02091141Neoplasms · United States2CompletedMay 24, 2023673
NCT01988896Solid Tumors · United States, Australia, Canada and more1CompletedNov 4, 2019153
NCT01986166Neoplasms · United States, Spain1CompletedJan 201623
NCT01974258Neoplasms · United States1WithdrawnJul 20140
NCT01929876Healthy Participants · United States1CompletedOct 201316
NCT01711762Healthy Volunteer · United States1CompletedSep 20126
NCT01689519Melanoma · United States, Australia, Austria and more3CompletedMay 9, 2014495
NCT01562275Neoplasms · United States, Spain1CompletedJan 201567
NCT01277718Healthy Volunteer1CompletedFeb 201120
NCT01271803Melanoma · United States, Australia1CompletedOct 1, 2013131
NCT01249131Healthy Volunteers1CompletedJan 10, 201120
NCT01249118Healthy Volunteers1CompletedJan 201113
NCT00996892Hereditary Sensory and Autonomic Neuropathies · United States1TerminatedMar 2014178
NCT00467779Solid Tumor · United States1CompletedApr 2014119

How it is read

Names in the registry

  • “Cobimetinib”, 34 entries
  • “cobimetinib”, 4 entries
  • “HM95573, cobimetinib”, 2 entries
  • “GDC-0973 IV Infusion”, 1 entry
  • “GDC-0973 Oral Capsules”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.